Insulet (NASDAQ:PODD) Price Target Raised to $375.00 at Wolfe Research

Insulet (NASDAQ:PODD) had its price objective raised by equities researchers at Wolfe Research from $350.00 to $375.00 in a report issued on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Wolfe Research’s target price indicates a potential upside of 15.27% from the stock’s current price.

Several other equities analysts have also commented on the company. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Oppenheimer lifted their price target on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Truist Financial upped their price objective on shares of Insulet from $365.00 to $390.00 and gave the stock a “buy” rating in a report on Friday. The Goldman Sachs Group decreased their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. Finally, Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average price target of $367.74.

Insulet Stock Up 0.6%

PODD traded up $1.93 on Friday, hitting $325.33. The company had a trading volume of 68,467 shares, compared to its average volume of 718,270. The stock has a fifty day simple moving average of $325.46 and a 200-day simple moving average of $308.84. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a market capitalization of $22.90 billion, a P/E ratio of 99.11, a P/E/G ratio of 2.64 and a beta of 1.39. Insulet has a 52-week low of $230.05 and a 52-week high of $353.50.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue for the quarter was up 29.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts expect that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Inspire Investing LLC boosted its stake in shares of Insulet by 299.5% in the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after buying an additional 3,088 shares during the last quarter. Gradient Investments LLC bought a new position in Insulet in the second quarter valued at about $17,429,000. Goldman Sachs Group Inc. lifted its holdings in Insulet by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after acquiring an additional 10,628 shares during the period. Vident Advisory LLC purchased a new position in Insulet in the first quarter worth about $216,000. Finally, Mn Services Vermogensbeheer B.V. grew its stake in shares of Insulet by 7.5% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 27,300 shares of the medical instruments supplier’s stock valued at $8,577,000 after purchasing an additional 1,900 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.